Physician profile
Aisha Shaikh
NPI 1508940842
$4,267.59
in general payments reported to CMS, 2019-2025
12 companies · $1,229 in 2025
The $1,229 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $67.23 · 2021: $192 · 2022: $179 · 2023: $1,959 · 2024: $641 · 2025: $1,229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,500 · Food and Beverage: $1,330 · Travel and Lodging: $925 · Education: $74.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,500.00 |
| Food and Beverage | $1,330.27 |
| Travel and Lodging | $925.30 |
| Education | $74.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,617.95 | 2021-2024 | Tavneos |
| Astrazeneca Uk Limited | $1,156.30 | 2025 | Saphnelo |
| Abbvie INC. | $654.93 | 2020-2024 | Rinvoq, Skyrizi, Humira |
| Pfizer INC. | $291.05 | 2020-2023 | |
| Travere Therapeutics, INC. | $145.60 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.75 | 2024 | Cyltezo |
| Novartis Pharmaceuticals Corporation | $94.95 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $74.00 | 2024 | Orencia |
| Janssen Biotech, INC. | $70.55 | 2021-2023 | Tremfya |
| Alexion Pharmaceuticals, INC. | $25.71 | 2022 | |
| Lilly USA, LLC | $20.77 | 2021 | |
| Novo Nordisk INC | $13.03 | 2023 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aisha Shaikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.